Industries > Pharma > Head and Neck Cancer Drugs Market Report 2019-2029

Head and Neck Cancer Drugs Market Report 2019-2029

Forecasts by Treatment (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy), by Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), by Distribution Channel (Hospitals, Online Providers, Drug Stores & Retail Pharmacies) Plus Analysis of Leading Companies

PAGES: 145
PRODUCT CODE: PHA0634

DOWNLOAD FREE SAMPLE
Clear
WOOCS 2.2.1

List of head and neck cancer drugs providers identified in this report are Bristol-Myers Squibb, Merck, Sanofi, Eli Lilly, AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Limited.

Head and Neck Cancer Drugs Market Report 2019-2029, By Treatment
– Surgery
– Radiation Therapy
– Chemotherapy
– Immunotherapy

Head and Neck Cancer Drugs Market Report 2019-2029, By Therapeutic Class
– PD Inhibitors
– EGFR Inhibitors
– Microtubule Inhibitors

Head and Neck Cancer Drugs Market Report 2019-2029, By Distribution Channel
– Hospitals
– Online Providers
– Drug stores & retail pharmacies

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Head and Neck Cancer Drugs Market Report 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Head and Neck Cancer Drugs Market Report 2019-2029


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category